Clinical Trials
46 trialsEvaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Celestimo
Hoffmann-La Roche
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
LEDA
Novartis
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
CLOVER-WaM
Cellectar Biosciences, Inc.
ALPHA2
Allogene Therapeutics
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Celgene
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
The Lymphoma Academic Research Organisation
MK-2140-004
Merck Sharp & Dohme LLC
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
PeproMene Bio, Inc.
OLYMPIA-2
Regeneron Pharmaceuticals
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
EPKEY_HSR
IRCCS San Raffaele
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
CLIO-1
Regeneron Pharmaceuticals
JKART-1
Gilead Sciences
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
IDA53
French Innovative Leukemia Organisation
TRANSCEND FL
Celgene
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
TGF-beta
Baylor College of Medicine
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Genmab
EPCORE DLBCL-2
Genmab
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
AbbVie
PORT
University College, London
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cullinan Therapeutics Inc.
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.